Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MAS825

Phase 2Small molecule

MAS825 is one of 35 small molecule programs targeting Still´s Disease. It is currently in Phase 2.

3

Indications

7

Total Trials

3

Active Trials

34

Competitors

Pipeline

Status by Indication[3][1]

Indication

Still´s DiseaseRecruiting

NLRC4-GOF, AIFEC (autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 MutationsActive, not recruiting

Hidradenitis SuppurativaActive, not recruiting

Still´s DiseasePhase 2

Recruiting

NLRC4-GOF, AIFEC (autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 MutationsPhase 2

Active, not recruiting

Hidradenitis SuppurativaPhase 2

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Hidradenitis Suppurativa

#DrugCompanyPhaseTrials

Otezla

Soriatane

Aldactone

Daliresp

Botox

RRevance Therapeutics, Inc.

Bimzelx

Jakafi

Glucophage

Rhapsido

Rinvoq

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Hidradenitis Suppurativa

NCT03827798

Q2 2028

Phase 2Recruiting

Still´s Disease

NCT07203001

Q4 2032

Phase 2Active, not recruiting

NLRC4-GOF, AIFEC (autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

NCT04641442

Clinical

Trials by Indication[1]

Clinical Trial1 trial

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

Completed·TThe Hospital for Sick Children·Phase 3·NCT06309823·1 enrolled

Tics1 trial

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 1·NCT04665154·80 enrolled

Heart Disease1 trial

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Completed· Novartis logo

Novartis·Phase 2·NCT06097663·31 enrolled

COVID-191 trial

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

Completed· Novartis logo

Novartis·Phase 2·NCT04382651·140 enrolled

Hidradenitis Suppurativa1 trial

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT03827798·248 enrolled

2 more indications

Still´s Disease1 trial

An Open-label Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Recruiting· Novartis logo

Novartis·Phase 2·NCT07203001·30 enrolled

NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations1 trial

A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blind, Placebo-controlled Design to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT04641442·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for MAS825. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MAS825 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MAS825. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

Related News